Dr. Mikhail Blagosklonny, an oncologist and researcher, known for making a significant influence in anti-ageing drug development. As a scientist in aging and cancer, he formulated hyperfunction theory that changed the concept of aging in the early 2000’s. It was previously believed that the aging was the functional decline due to the molecular damage, and it cannot be prevented. The theory put forward by Blagosklonny stated that aging is just a continuation of growth that is driven by some sort of signaling pathways such as Target of Rapamycin (TOR). The theory paved ways for further research on anti-aging drugs with the initial development of Everolimus, a rapamycin analog, in 2008. After more than six years of experiments, the analog shows improvements in the immunity of old humans, as predicted by Dr. Blagosklonny.
The TOR-centric model suggested that rapamycin and other rapalogs could be used for treating aging and preventing diseases. It further said that with proper schedules and doses, rapamycin would extend the healthier lifespan of humans. Though the critics ridiculed the theory initially, now, they are forced to accept the effectiveness of TOR-centric model with the proven results. Currently, many of the pharmaceutical firms are chasing down the rapamycin analogs, and Novartis confirmed that it is in the works of developing a ‘Fountain of Youth’ Drug” that can delay the effects of aging. Visit classroomvoices.org to read more about Mikhail.
The hyperfunction theory suggested the calorie-restriction-mimicking characteristic and side-effects of rapalogs in the initial days. For instance, rapamycin increases lipolysis to imitate fasting. Additionally, it can cause “starvation diabetes” in some cases that creates glucose intolerance and insulin resistance. This induced state can stop the complications of type II diabetes. The MTOR-centric model proposed that the restorable insulin resistance can cause increased longevity as the longevity is promoted by the decreased mTOR signaling. The TOR-centric model identified that the growth-promoting signaling at the initial years of growth is becoming harmful in the later part of the life and cause aging. Dr. Blagosklonny also confirmed three sources of the TOR-centric model, which is the genetics of longevity, cellular senescence, and diseases.
Dr. Blagosklonny is a professor of Oncology at the reputed Roswell Park Cancer Institute with research on cancer and aging. He started his career with New York Medical College as an associate professor of medicine. Later, Dr. Blagosklonny moved to Ordway Research Institute and served there as a senior scientist. In 2009, he joined Roswell Park with research interests in Biogerontology, anti-aging drugs, targeted cancer therapies, and more.
Dr. Blagosklonny is closely associated with many medical journals. He is the editor-in-chief of Cell Cycle and Oncotarget. Dr. Mikhail Blagosklonny is also working on cancer biology and therapy, PLOS ONE, International Journal of Cancer, and the American Journal of Pathology as their associate editor and serves on the editorial board of Cell Death and Differentiation. He has published more than 300 research papers, reviews, and book chapters. Dr. Blagosklonny earned his medical graduation from the First Pavlov State Medical University and later completed his M.D. in Internal Medicine. He also did a Ph.D. in Cardiology and Experimental Medicine from the same university.